Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana.
Adolescent
Adult
Bacterial Load
Buruli Ulcer
/ drug therapy
CD4 Lymphocyte Count
Coinfection
/ epidemiology
Female
Ghana
/ epidemiology
HIV Infections
/ drug therapy
Humans
Male
Middle Aged
Mycobacterium ulcerans
/ genetics
Prevalence
RNA, Ribosomal, 16S
Real-Time Polymerase Chain Reaction
Retrospective Studies
Viral Load
Wound Healing
Young Adult
Antiretroviral therapy
Buruli ulcer
Coinfection
Human immunodeficiency syndrome
Immune reconstitution syndrome
Interferon-gamma
Mycolactone
Paradoxical reaction
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
received:
20
11
2020
accepted:
22
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Previous studies have reported that presence and severity of Buruli ulcer (BU) may reflect the underlying immunosuppression in HIV infected individuals by causing increased incidence of multiple, larger and ulcerated lesions. We report cases of BU-HIV coinfection and the accompanying programmatic challenges encountered in central Ghana. Patients with PCR confirmed BU in central Ghana who were HIV positive were identified and their BU01 forms were retrieved and reviewed in further detail. A combined 16S rRNA reverse transcriptase / IS2404 qPCR assay was used to assess the Mycobacterium ulcerans load. The characteristics of coinfected patients (BU The prevalence of HIV in this BU cohort was 2.4% (compared to national HIV prevalence of 1.7%). Eight of 9 BU The prevalence of HIV in the BU+ infected population was not significantly increased when compared to the prevalence of HIV in the general population. There was no clear relationship between BU lesion severity and HIV viral load or CD4 counts. Efforts should be made to encourage the integration of care of patients with BU-HIV coinfection.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have reported that presence and severity of Buruli ulcer (BU) may reflect the underlying immunosuppression in HIV infected individuals by causing increased incidence of multiple, larger and ulcerated lesions. We report cases of BU-HIV coinfection and the accompanying programmatic challenges encountered in central Ghana.
METHODS
METHODS
Patients with PCR confirmed BU in central Ghana who were HIV positive were identified and their BU01 forms were retrieved and reviewed in further detail. A combined 16S rRNA reverse transcriptase / IS2404 qPCR assay was used to assess the Mycobacterium ulcerans load. The characteristics of coinfected patients (BU
RESULTS
RESULTS
The prevalence of HIV in this BU cohort was 2.4% (compared to national HIV prevalence of 1.7%). Eight of 9 BU
CONCLUSION
CONCLUSIONS
The prevalence of HIV in the BU+ infected population was not significantly increased when compared to the prevalence of HIV in the general population. There was no clear relationship between BU lesion severity and HIV viral load or CD4 counts. Efforts should be made to encourage the integration of care of patients with BU-HIV coinfection.
Identifiants
pubmed: 33832460
doi: 10.1186/s12879-021-06009-7
pii: 10.1186/s12879-021-06009-7
pmc: PMC8028811
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
331Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/J01477X/1
Pays : United Kingdom
Références
Cell Microbiol. 2016 Jan;18(1):17-29
pubmed: 26572803
Lancet Infect Dis. 2014 May;14(5):435-40
pubmed: 24309480
PLoS Negl Trop Dis. 2012 Jan;6(1):e1460
pubmed: 22253937
Clin Vaccine Immunol. 2009 Jan;16(1):61-5
pubmed: 19005025
AIDS. 2002 Aug 16;16(12):1704-5
pubmed: 12172103
J Immunol. 2010 Jan 15;184(2):947-55
pubmed: 20008288
Case Rep Med. 2013;2013:348628
pubmed: 24454398
Curr Trop Med Rep. 2018;5(4):247-256
pubmed: 30460172
PeerJ. 2018 Jul 31;6:e5294
pubmed: 30090691
Clin Diagn Lab Immunol. 2005 Dec;12(12):1425-8
pubmed: 16339066
Emerg Infect Dis. 2009 Sep;15(9):1351-8; quiz 1544
pubmed: 19788801
Lancet. 2020 Apr 18;395(10232):1259-1267
pubmed: 32171422
Am J Trop Med Hyg. 2015 Aug;93(2):216-23
pubmed: 26055745
PLoS Negl Trop Dis. 2016 Feb 10;10(2):e0004450
pubmed: 26863011
PLoS One. 2019 Apr 19;14(4):e0215377
pubmed: 31002687
PLoS Negl Trop Dis. 2014 May 22;8(5):e2904
pubmed: 24853088
Cell Microbiol. 2005 Sep;7(9):1295-304
pubmed: 16098217
PLoS Negl Trop Dis. 2019 Aug 26;13(8):e0007689
pubmed: 31449522
PLoS Negl Trop Dis. 2012;6(8):e1756
pubmed: 22953006
J Cell Sci. 2016 Apr 1;129(7):1404-15
pubmed: 26869228
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005695
pubmed: 28671942
BMC Infect Dis. 2014 Jul 30;14:423
pubmed: 25073531
Mol Diagn. 2004;8(2):107-13
pubmed: 15527325
Clin Vaccine Immunol. 2006 Dec;13(12):1314-21
pubmed: 17021247
Clin Microbiol Rev. 2017 Dec 13;31(1):
pubmed: 29237707
Clin Infect Dis. 2003 Apr 15;36(8):1076-7
pubmed: 12684923
Open Forum Infect Dis. 2014 May 21;1(1):ofu021
pubmed: 25734094